secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001104659-23-088628
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics Q2 2023: $34.2M cash, VCN-01 trial on track, FDA orphan drug
------------------------------------------------------------------------------

- Cash and equivalents $34.2M as of June 30, 2023, expected runway into Q4 2024.
- VIRAGE Phase 2b trial (VCN-01 + chemo) enrollment on track to complete Q1 2024; US sites dosing initiated.
- FDA granted orphan drug designation to VCN-01 for pancreatic cancer; previously for retinoblastoma.
- Ramon Alemany, Ph.D., appointed SVP of Discovery; continues as chair of Scientific Advisory Board.
- G&A expenses rose 80% to $2.7M; R&D expenses fell 10% to $3.1M vs Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465923088628/0001104659-23-088628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465923088628/tm2322993d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer